Literature DB >> 20139394

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment.

Angel F Remacha, Beatriz Arrizabalaga, Javier Bueno, Juan Muñoz, Joan Bargay, Carme Pedro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20139394      PMCID： PMC2817041          DOI： 10.3324/haematol.2009.016956

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Authors:  B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.

Authors:  A John Barrett; Elaine Sloand
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

3.  Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.

Authors:  David P Steensma; Angela Dispenzieri; S Breanndan Moore; Georgene Schroeder; Ayalew Tefferi
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

4.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

Authors:  Luca Malcovati; Matteo Giovanni Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Marina Boni; Erica Travaglino; Francesco Passamonti; Luca Arcaini; Margherita Maffioli; Paolo Bernasconi; Mario Lazzarino; Mario Cazzola
Journal:  J Clin Oncol       Date:  2005-09-26       Impact factor: 44.544

5.  Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.

Authors:  A F Remacha; B Arrizabalaga; A Villegas; R Manteiga; T Calvo; A Julià; I Fernández Fuertes; F A González; L Font; J Juncà; A del Arco; J J Malcorra; E P Equiza; B P de Mendiguren; M Romero
Journal:  Haematologica       Date:  1999-12       Impact factor: 9.941

6.  Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

Authors:  Martin Jädersten; Scott M Montgomery; Ingunn Dybedal; Anna Porwit-MacDonald; Eva Hellström-Lindberg
Journal:  Blood       Date:  2005-04-19       Impact factor: 22.113

7.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

8.  Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study.

Authors:  Rami Kotb; Caroline Pinganaud; Catherine Trichet; Olivier Lambotte; Marie Dreyfus; Jean-François Delfraissy; Gil Tchernia; Cécile Goujard
Journal:  Eur J Haematol       Date:  2005-07       Impact factor: 2.997

9.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

Authors:  Eva Hellström-Lindberg; Nina Gulbrandsen; Greger Lindberg; Tomas Ahlgren; Inger Marie S Dahl; Ingunn Dybedal; Gunnar Grimfors; Eva Hesse-Sundin; Martin Hjorth; Lena Kanter-Lewensohn; Olle Linder; Michaela Luthman; Eva Löfvenberg; Gunnar Oberg; Anja Porwit-MacDonald; Anders Rådlund; Jan Samuelsson; Jon Magnus Tangen; Ingemar Winquist; Finn Wisloff
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

Review 10.  Immunosuppressive treatments for myelodysplastic syndromes.

Authors:  Takashi Shimamoto; Kazuma Ohyashiki
Journal:  Leuk Lymphoma       Date:  2003-04
View more
  3 in total

1.  Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis.

Authors:  Maximilian Stahl; Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Amer M Zeidan
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

Review 2.  Immune Mechanisms in Myelodysplastic Syndrome.

Authors:  Andreas Glenthøj; Andreas Due Ørskov; Jakob Werner Hansen; Sine Reker Hadrup; Casey O'Connell; Kirsten Grønbæk
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

3.  Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines.

Authors:  Motohiko Murase; Hiroyuki Iwamura; Kensuke Komatsu; Motoki Saito; Toshihiko Maekawa; Takaaki Nakamura; Takuya Yokokawa; Yasuhiro Shimada
Journal:  Pharmacol Res Perspect       Date:  2016-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.